Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Young Prostate versus standard therapy for benign prostatic hyperplasia with overactive bladder
IRCT20120215009014N386Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of terazosin, finasteride and oxybutynin in benign prostatic hyperplasia (BPH) and overactive bladder (OAB) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Sexual desire and Prostate size. Started Apr 2021; status: completed.
02
Drugs
terazosinfinasterideoxybutynin
03
Conditions
benign prostatic hyperplasia (BPH)overactive bladder (OAB)
Beyond the preview
Go deeper on IRCT20120215009014N386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N386.